There is no approved therapy for coronavirus disease 2019 (COVID-19) \[severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection\], and the number of worldwide deaths on current standard therapy is staggering \[[@sfaa095-B1]\]. Current therapy is aimed at decreasing viral replication, supporting vital functions and addressing the most damaging consequences of the disease such as hyperinflammation (the so-called cytokine storm) and thrombosis. The latter two involve the use of anti-inflammatory therapies and heparin, respectively. We suggest that complement-blocking strategies such as eculizumab should be considered in severe cases not responding well to current therapy, including tocilizumab, in the context of clinical trials. Complement is thought to contribute to microangiopathies associated with infectious diseases \[[@sfaa095-B2]\].

Recent histological data from COVID-19 patients are compatible with acute respiratory distress syndrome (ARDS) \[[@sfaa095-B3]\]. Additionally, vascular congestion and inflammatory cell infiltrates were present \[[@sfaa095-B4]\], as well as microvascular thrombi in multiple organs including kidneys in patients who died of COVID-19 and SARS \[[@sfaa095-B5], [@sfaa095-B6]\]. Immunohistochemically, deposits of C5b-9, C4d and mannose-binding lectin-associated serine protease-2 have been found in the microvasculature of lungs and skin in patients with COVID-19 \[[@sfaa095-B7]\]. Furthermore, COVID-19 shares some features with entities that are complement mediated, such as disseminated intravascular coagulation, thrombotic microangiopathy (TMA) and antiphospholipid antibody syndrome. These include increased lactate dehydrogenase (LDH) , platelet disease, hypertransaminasaemia, anaemia and extrapulmonary involvement, such as the kidney or heart ([Table 1](#sfaa095-T1){ref-type="table"}) \[[@sfaa095-B5]\]. However, we have not found alterations in haptoglobin or the presence of schistocytes to date.

###### 

Comparison between clinical situations belonging to a combined inflammatory--microthrombotic syndrome related to COVID-19

  Characteristics                  COVID-19                                                TMA                                                                                                                  DIC                                                                       APS
  -------------------------------- ------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  Anaemia                          Often                                                   Usually (haemolytic)                                                                                                 Often                                                                     Rare (haemolytic)
  Thrombopenia                     \+                                                      +++                                                                                                                  ++                                                                        \+
  Haptoglobin                      Unknown                                                 Low                                                                                                                  Normal                                                                    Low/normal
  LDH                              High                                                    High                                                                                                                 Often high                                                                High/normal
  Hypertransaminasaemia            Yes                                                     Yes                                                                                                                  No                                                                        Rare
  Schistocytes                     Unknown                                                 Yes                                                                                                                  Yes                                                                       Rare
  D-Dimer                          High                                                    Normal                                                                                                               High                                                                      Normal/high
  Fibrinogen                       High                                                    Normal                                                                                                               Low                                                                       Normal/high
  Coagulation tests                Altered                                                 Normal                                                                                                               Altered                                                                   Altered
  Anti-phospholipid antibodies     Rare                                                    No                                                                                                                   No                                                                        AnticardiolipinAnti-beta2-glycoprotein ILupus anticoagulant
  Histology                        Endothelial damage Microvascular thrombi                Microvascular fibrin thrombi                                                                                         Thrombosis in small and midsize vessels                                   Arterial and venous thrombosis
  Serum complement (C3-C4)         Normal/high?                                            Low/normal                                                                                                           Low/normal                                                                Low
  Vascular complement deposition   C5b-9/C4d                                               C5b-9                                                                                                                No                                                                        C5b-9
  Extrapulmonary involvement       Yes                                                     Yes                                                                                                                  Yes                                                                       Yes
  Therapy                          Supportive therapyAnticoagulant (heparin)?Eculizumab?   Supportive therapyBlood transfusion (RBC, FFP)PE/FFPhaemodialysis (HUS)Eculizumab (aHUS)DescriptionRituximab (TTP)   Supportive therapyBlood transfusion (RBC, FFP, PC)AnticoagulantAC, rhTM   AnticoagulantCorticosteroidsIntravenous immunoglobinCyclophosphamideRituximab?Eculizumab?

DIC, disseminated intravascular coagulation; APS, anti-phospholipid syndrome; RBC, red blood cells; FFP, fresh frozen plasma ; PE, plasma exchange; HUS, haemolytic uraemic syndrome; aHUS, atypical haemolytic uraemic syndrome; TTP, thrombotic thrombocytopenic purpura ; PC, platelet concentrate; AC, antithrombin concentrate; rhTM, recombinant human thrombomodulin.

A related virus, SARS-CoV, promotes complement activation, increasing C5a levels and contributing to hyperinflammation \[[@sfaa095-B11]\]. Generally speaking, sepsis or critical injury (e.g. in the context of COVID-19) will activate immune cells that cause endothelial dysfunction, resulting in the activation of two molecular pathways: further inflammation and microthrombosis associated with complement activation and excess thrombin generation \[[@sfaa095-B2], [@sfaa095-B9]\]. Microthrombi may have different clinical manifestations depending on the most affected organ, such as ARDS in the lung, acute renal failure and haemolytic uraemic syndrome or acute myocardial infarction, among others \[[@sfaa095-B2]\]. While complement protects from infection, dysregulated complement activation could cause TMA and contribute to ARDS as suggested for other coronaviruses \[[@sfaa095-B2], [@sfaa095-B5], [@sfaa095-B12]\]. Additionally, in the context of inflammation, non-complement proteases, such as thrombin, a coagulation pathway protein \[[@sfaa095-B13]\], and proteases from neutrophils and macrophages can generate C5a from C5, independently from the plasma complement system \[[@sfaa095-B14]\]. We agree with Campbell that severe COVID-19 manifestations have commonalities with thrombotic microangiopathies that respond to the C5a complement inhibitor eculizumab \[[@sfaa095-B6], [@sfaa095-B15]\]. In this regard, anti-complement therapies should be part of clinical trials with well-defined entry criteria for a combined inflammatory--microthrombotic syndrome and integrating the approach within the current therapeutic algorithm for COVID-19 \[[@sfaa095-B1]\]. Indeed, two Phase 2 clinical trials testing eculizumab for patients with severe COVID-19 are scheduled to start soon or have started in April 2020 (NCT04288713, NCT04346797).

Furthermore, the relative contribution of anticoagulation and complement targeting should be defined \[[@sfaa095-B16]\]. It is likely that anticoagulation targets a relatively late event that may be driven by earlier complement activation and endothelial injury \[[@sfaa095-B2]\]. In order to clarify this hypothesis, we have designed a scheme ([Figure 1](#sfaa095-F1){ref-type="fig"}).

![Proposed pathogenesis for COVID-19, adapted from Chang \[[@sfaa095-B2]\], which includes endothelial dysfunction as the origin of the damage and the two main pathways. The first is the inflammatory pathway that would be related to the activation of monocytes--macrophages triggering the 'cytokine storm' leading to a systemic inflammatory response syndrome that usually occurs in association with ARDS and, ultimately, multi-organ failure. The second is the microthrombotic , closely related to activation of the complement, platelet and coagulation disorders. Also, there are factors that interact with both pathways, for example, the inducible serine protease that activates C5; some cytokines favour the development of disseminated intravascular coagulation and hypoxia favours a prothrombotic state *per se* by stimulating thrombin.](sfaa095f1){#sfaa095-F1}
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